UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): July 17,
2018
AZURRX BIOPHARMA, INC.
(Exact name of Registrant as specified in its Charter)
|
Delaware
|
001-37853
|
46-4993860
|
|
(State or Other
Jurisdiction of
Incorporation or
Organization)
|
(Commission File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
|
760 Parkside Avenue
Downstate Biotechnology Incubator,
Suite 304
Brooklyn, New York
|
|
11226
|
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
Registrant’s telephone number, including area code:
(646) 699-7855
(Name,
address, including zip code, and telephone number, including area
code, of agent for service of process)
NOT
APPLICABLE
(Former
Name or Former Address, if Changes Since Last Report)
Check
the appropriate box below if the Form 8-K is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions):
[
] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR 240.12b-2) ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act ☐
|
Item 5.08
|
Shareholder Director Nominations.
|
The Board of Directors of AzurRx
BioPharma, Inc. (the “Company”) has approved August 27, 2018 as the date
for the Company’s 2018 Annual Meeting of Stockholders (the
“Annual
Meeting”). This date is
more than 30 days before the anniversary of the Company’s
2017 Annual Meeting of Stockholders. As a result, in accordance
with the applicable rules and regulations of the Securities
and Exchange Commission (the “SEC”), written notice from a stockholder
interested in bringing business before the Annual Meeting or
nominating a director candidate for election at the Annual Meeting
(including any notice on Schedule 14N) must be received by no later
than 5:00 p.m., Eastern time, on July 23, 2018 at the
Company’s principal executive offices, 760 Parkside Avenue,
Downstate Biotechnology Incubator, Suite 304, Brooklyn, New York
11226. Any such written notice must be directed to the attention of
the Company’s Secretary, and must comply with all applicable
rules and regulations promulgated by the SEC under the
Securities Exchange Act of 1934, as amended (the
“Exchange
Act”). Stockholder
proposals intended to be considered for inclusion in the
Company’s proxy materials for the Annual Meeting must also
comply with all applicable rules and regulations promulgated
by the SEC under the Exchange Act.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AzurRx BioPharma,
Inc.
|
|||
|
|
|
|
|
|
Date: July 17,
2018
|
By:
|
/s/ Johan M.
Spoor
|
|
|
|
|
Name: Johan M. Spoor
|
|
|
|
|
Title: Chief Executive Officer
|
|